Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 105 of 1,261
  1. US 12043655

    Constitutively active chimeric cytokine receptors

    Allogene Therapeutics, Inc. Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  2. US 12043629

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  3. US 12043601

    N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same

    The Regents of the University of Colorado Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  4. US 12043831

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  5. US 12043607

    HDAC inhibitors and therapeutic use thereof

    Tango Therapeutics, Inc. Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  6. US 12043610

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  7. US 12043843

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  8. US 12043833

    Targeted compositions

    ARBUTUS BIOPHARMA CORPORATION Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  9. US 12043660

    10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jul 23, 2024 Β· Expires Jul 18, 2044

    granted
  10. WO 2024149832

    SARNA (VRP) MODIFIÉ RECOMBINANT POUR VACCIN CONTRE LE CANCER

    BAVARIAN NORDIC AS [DK] Β· Granted Jul 18, 2024 Β· Expires Jul 13, 2044

    granted
  11. US 12036288

    Methods of using humanized FCΞ³R mice to assay Fc regions

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  12. US 12036280

    High concentration protein formulation

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  13. US 12038433

    Methods and apparatus for high-throughput screening for testing permeability and retention of compounds across biological barriers

    The Board of Regents of the University of Texas System Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  14. US 12037616

    Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

    CRISPR THERAPEUTICS AG Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  15. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Nektar Therapeutics Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  16. US 12036241

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  17. US 12037411

    Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  18. US 12036198

    Dosage forms and therapeutic uses of L-4-chlorokynurenine

    VISTAGEN THERAPUETICS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  19. US 12037374

    Peptides, hydrogel compositions and methods of use thereof

    Regents of the University of Minnesota Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  20. US 12035713

    Pest control using natural pest control agent blends

    TYRATECH, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  21. US 12036243

    BCMA CAR-T cells with enhanced activities

    Allogene Therapeutics, Inc. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  22. US 12036256

    Adoptive cellular therapy

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  23. US 12036234

    Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues

    Northwestern University Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  24. US 12037363

    Peptides for Covid-19 prevention and treatment

    SOTIRA COVID, LLC Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.